human vaccine
Improving Human Wellness Through Innovative Recombinant Protein Biotechnology
Acute nausea, uncontrolled vomiting and diarrhea
highly contagious and resistant to environmental condition
hundreds of millions of cases each year with up to 200,000 deaths in children < 5 years of age
Potential market : Military, School, Hospital & Traveler..
Lack of in vitro culture system ▶ VLP is the only means for vaccine development
High genetic diversity : Five genogroup & minimum twenty five serotype ▶ Multivalent vaccine development is mandatory
Production of VLP in E.coli through the use of platform technology, RIPT.
High-yield and fast manufacturing of VLP with cost-effectiveness
Development of multivalent vaccine against multiple strains of norovirus
A febrile illness characterized by maculopapular rash or blisters on the hands,
soles, and buttocks
and is associated with painful ulcerative lesions of the mouth.
Enterovirus 71 (EV71) and Coxsackievirus A16(COX A16) are the predominant cause of HFMD
EV71 is neurotropic virus responsible for severe CNS complication which is associated with high mortality
In recent years numerous outbreaks of HFMD has occurred and caused significant morbidity and mortality. (in 2010, 1.8 mil. cases and 905 deaths in China)
In the absence of effective treatment, large scale HFMD outbreaks have a major impact on healthcare and daycare systems.
Highly contagious and genetic variability of EV71 & Cox A 16 ▶ multivalent vaccine development is mandatory
High-yield and fast production of VLP in E.coli through the use of platform technology, RIPT.
Development of multivalent vaccine against multiple strains of EV 71 & Cox A 16 virus.